Drugs
Warning Letters 2008
2008 Warning Letters and Untitled Letters to Pharmaceutical Companies
These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office. This page only covers Division of Drug Marketing and Communications and Headquarters Warning Letters. For District Office Warning Letters see the Main FDA FOI Warning Letters Page. Some of the letters have been redacted or edited to remove confidential information. Click on the links in each month to view the letters in Adobe Acrobat format. [more...]
December 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Abbott Laboratories | Division of Drug Marketing, Advertising, and Communications | 12/16/2008 | 12/23/2008 | |
AstraZeneca | Division of Drug Marketing, Advertising, and Communications | 12/1/2008 | 12/4/2008 | |
Victory Pharma, Inc. | Division of Drug Marketing, Advertising, and Communications | 12/12/2008 | 12/15/2008 |
November 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Cedax (ceftibuten capsules and ceftibuten for oral suspension) (Warning Letter) | Shionogi USA, Inc. | Division of Drug Marketing, Advertising, and Communications | 11/14/2008 | 11/20/2008 |
Actelion Pharmaceuticals US, Inc. | Division of Drug Marketing, Advertising, and Communications | 11/24/2008 | 11/25/2008 | |
Protherics, Inc. | Division of Drug Marketing, Advertising, and Communications | 11/14/2008 | 11/20/2008 |
October 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Bayer Aspirin with Hearth Advantage (Warning Letter) | Bayer HealthCare L.L.C. | Division of New Drugs & Labeling Compliance | 10/27/2008 | 10/28/2008 |
Bayer Women's Low Dose Aspirin + Calcium (Warning Letter) | Bayer HealthCare L.L.C. | Division of New Drugs & Labeling Compliance | 10/27/2008 | 10/28/2008 |
Clinical Investigator (Warning Letter) | Richard Holub, M.D. | Division of Scientific Investigations. | 10/1/2008 | 10/24/2008 |
Amgen | Division of Drug Marketing, Advertising, and Communications | 10/27/2008 | 10/29/2008 | |
SINUS SCIENCE Aerosol Medication Delivery System (Warning Letter) | Aerosol Science Laboratories Inc. | Division of New Drugs & Labeling Compliance | 10/29/2008 | 11/14/2008 |
YAZ (drospirenone and ethinyl estradiol) Tablets (Warning Letter) | Bayer HealthCare Pharmaceuticals, Inc. | Division of Drug Marketing, Advertising, and Communications | 10/3/2008 | 10/7/2008 |
September 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Adderall XR Capsules (Warning Letter) | Shire Development | Division of Drug Marketing, Advertising, and Communications | 9/25/2008 | 9/26/2008 |
Clinical Investigator (Warning Letter) | Gregory Gardziola | Division of Scientific Investigations | 9/3/2008 | 10/24/2008 |
Johnson & Johnson | Division of Drug Marketing, Advertising, and Communications | 9/25/2008 | 9/26/2008 | |
Novartis Pharmaceuticals | Division of Drug Marketing, Advertising, and Communications | 9/25/2008 | 9/26/2008 | |
Mallinckrodt Inc. | Division of Drug Marketing, Advertising, and Communications | 9/25/2008 | 9/26/2008 | |
Mirapex (pramipexole dihydrochloride) (Warning Letter) | Boehringer-Ingelheim | Division of Drug Marketing, Advertising, and Communications | 9/29/2008 | 10/2/2008 |
Strattera (atomoxetine HCl) (Warning Letter) | Eli Lilly & Company | Division of Drug Marketing, Advertising, and Communications | 9/25/2008 | 9/26/2008 |
Ranbaxy Laboratories Limited | Division of Manufacturing and Product Quality | 9/16/2008 | 9/16/2008 |
August 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Bystolic (nebivolol) Tablets (Warning Letter) | Forest Laboratories, Inc. | Division of Drug Marketing, Advertising, and Communications | 8/28/2008 | 9/8/2008 |
Novartis Pharmaceuticals | Division of Drug Marketing, Advertising, and Communications | 8/28/2008 | 9/26/2008 | |
Institutional Review Board (Warning Letter) | Hospital Municipal de San Juan IRB | Division of Scientific Investigations | 8/15/2008 | 8/20/2008 |
June 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Clinical Investigator (Warning Letter) | Nagarjuna R. Ponugoti, M.D. | Division of Scientific Investigations | 6/6/2008 | 7/9/2008 |
Sponsor-Applicant-Monitor-CRO (Warning Letter) | Travanti Pharma, Inc. | Division of Scientific Investigations | 6/30/2008 | 7/2/2008 |
May 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Clinical Investigator (Warning Letter) | Arturo Corces, M.D. | Division of Scientific Investigations | 5/28/2008 | 7/9/2008 |
Sponsor-Investigator (Warning Letter) | Willa A. Hsueh, M.D. | Division of Scientific Investigations | 5/30/2008 | 7/9/2008 |
Sponsor/Investigator (Warning Letter) | Edward Mostel, M.D.. | Division of Scientific Investigations | 5/16/2008 | 7/9/2008 |
Shire Development, Inc. | Division of Drug Marketing, Advertising, and Communications | 5/1/2008 | 5/8/2008 | |
Trileptal (Warning Letter) | Novartis Pharmaceuticals Corporation | Division of Drug Marketing, Advertising, and Communications | 5/1/2008 | 5/8/2008 |
April 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Inspection (Warning Letter) | Changzhou SPL Company, Ltd. | Division of Manufacturing and Product Quality | 4/21/2008 | 4/21/2008 |
Peridex (Warning Letter) | Zila Pharmaceuticals, Inc. | Division of Drug Marketing, Advertising, and Communications | 4/18/2008 | 4/22/2008 |
Viagra (Warning Letter) | Pfizer, Inc. | Division of Drug Marketing, Advertising, and Communications | 4/16/2008 | 4/21/2008 |
March 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Avinza (Warning Letter) | King Pharmaceuticals, Inc. | Division of Drug Marketing, Advertising, and Communications | 3/24/2008 | 3/26/2008 |
Clinical Investigator (Warning Letter) | Saroj Brar, M.D. | Division of Scientific Investigations | 3/20/2008 | 4/22/2008 |
Clinical Investigator (Warning Letter) | Ashok Shah, M.D. | Division of Scientific Investigations | 3/19/2008 | 4/22/2008 |
Clinical Investigator (Warning Letter) | Frank Whittier, M.D. | Division of Scientific Investigations | 3/6/2008 | 4/22/2008 |
Institutional Review Board (Warning Letter) | Coast Institutional Review Board | Division or Scientific Investigations | 3/11/2008 | 3/26/2008 |
February 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Clinical Investigator (Warning Letter) | Kevin W. Klein, M.D. | Division or Scientific Investigations | 2/13/2008 | 2/28/2008 |
Clinical Investigator (Warning Letter) | Nasim Golzar, MD | Division of Scientific Investigations | 2/13/2008 | 5/15/2008 |
Institutional Review Board (Warning Letter) | West Jefferson Medical Center IRB | Division of Scientific Investigations | 2/25/2008 | 4/1/2008 |
January 2008
Product/Issue | Company/Individual | Division | Released | Posted |
---|---|---|---|---|
Sponsor-Applicant-Monitor-Clinical Research Organization (Warning Letter) | Replidyne, Inc. | Division or Scientific Investigations | 1/18/2008 | 2/15/2008 |
Inspection (Warning Letter) | Tomita Pharmaceutical Co., Ltd | Division of Manufacturing and Product Quality | 1/14/2008 | 1/23/2008 |
Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane, Rockville, MD 20857
Instructions for how to submit an FOI request can be found on the FDA FOI Page.
The letters are arranged in chronological order by month.